Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the ...

Quick Read Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the ...

History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Eli Lilly stock (NYSE: LLY) should be on your radar. Here’s why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly. Over ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. Eli Lilly's (NYSE ...

We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

The recent rotation into healthcare stocks and out of hot technology plays can be epitomized by the strong outperformance of Eli Lilly shares relative to Nvidia’s stock. Since the tech sector peaked ...